Is Vraylar a Mood Stabilizer?
Vraylar (cariprazine) is FDA-approved as an atypical antipsychotic for treating acute manic/mixed episodes and depressive episodes in bipolar I disorder, but it is not technically classified as a traditional "mood stabilizer" in the classical sense 1.
Understanding the Terminology
The term "mood stabilizer" is widely used but imprecise. Traditional mood stabilizers (lithium, valproate) primarily demonstrate efficacy for acute manic symptoms rather than stabilizing mood across all phases of bipolar disorder 2. The term "antimanic" may be more accurate for most agents used in bipolar disorder 2.
Vraylar's FDA-Approved Indications
According to the FDA label, Vraylar is approved for 1:
- Acute manic or mixed episodes in bipolar I disorder (adults and children ≥10 years)
- Depressive episodes in bipolar I disorder (adults only)
- Schizophrenia (adults and children ≥13 years)
- Adjunctive treatment of major depressive disorder (adults only)
Evidence for Mood Episode Treatment
Acute Mania
Cariprazine demonstrates moderate efficacy in reducing manic symptoms with significant reductions in YMRS scores (SMD: -0.52), higher remission rates (OR: 2.05), and response rates (OR: 2.31) compared to placebo 3.
Bipolar Depression
Cariprazine at 1.5-3 mg/day shows efficacy for acute bipolar depression, though effect sizes are smaller (SMD: -0.26 to -0.21) 3, 4. It significantly reduces MADRS scores (MD = -2.53) with higher response (RR = 1.27) and remission rates (RR = 1.41) in bipolar I depression 4.
Full-Spectrum Activity
Cariprazine appears to address symptoms from both manic and depressive poles without precipitating mood destabilization or treatment-emergent affective switch (TEAS) 5. This "full-spectrum" activity across mood poles is notable, as lower percentages of cariprazine-treated patients experienced TEAS compared to placebo 5.
Critical Limitation: Maintenance/Prevention
The most significant gap is that cariprazine failed to demonstrate superiority over placebo in preventing mood episode relapses 6. In a 2024 phase 3b maintenance study, relapse rates were similar between cariprazine (17.9% for 3mg, 16.8% for 1.5mg) and placebo (19.7%), with unusually low placebo relapse rates 6. This means cariprazine lacks proven efficacy for long-term mood stabilization or relapse prevention, which is a core function expected of true "mood stabilizers."
Clinical Bottom Line
Vraylar functions as an effective acute treatment for both manic and depressive episodes in bipolar I disorder, but it is not a mood stabilizer in the traditional sense because it has not demonstrated efficacy in preventing future mood episodes 6. It is more accurately described as an atypical antipsychotic with antimanic and antidepressant properties in bipolar disorder.
When to Use Vraylar
- Acute manic or mixed episodes: Effective option alongside traditional mood stabilizers
- Acute bipolar depression: Monotherapy option with demonstrated efficacy 7, 3
- Adjunctive therapy: Can be combined with traditional mood stabilizers for acute episodes 2
Important Caveats
- Not proven for maintenance therapy or relapse prevention 6
- Traditional mood stabilizers (lithium, valproate) remain the backbone for long-term bipolar management 2
- Tolerability concerns include akathisia, weight gain, and extrapyramidal symptoms 1, 3
- Higher discontinuation rates due to adverse events compared to placebo 4